PA
CTS icon

PharVision Advisers’s CTS Corp CTS Stock Holding History

PharVision Advisers’s Portfolio CTS Stock Details CTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6,161
Closed -$246K – 745
2025
Q3 		$246K Buy
+6,161
New +$255K 0.14% 345

Other funds holding CTS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FMI
Fiduciary Management Inc Milwaukee, Wisconsin $8.06B AUM 6.78% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PharVision Advisers's CTS Position: Q4 2025 in Review

PharVision Advisers sold out of CTS Corp (CTS) in Q4 2025, closing a stake of 6,161 shares — an estimated $246K sold.

PharVision Advisers first reported a position in CTS in Q3 2025 and held it in 1 quarter. The position peaked at $246K in Q3 2025. 223 funds tracked by Wall St. Rank hold CTS as of Q4 2025.

  • PharVision Advisers reported no remaining CTS Corp position as of Q4 2025 after selling out during the quarter.
  • PharVision Advisers sold 6,161 CTS Corp shares in Q4 2025, an estimated $246K.
  • PharVision Advisers first reported a position in CTS Corp in Q3 2025 and held it in 1 quarter.
  • PharVision Advisers's CTS Corp position peaked at $246K in Q3 2025.
  • 223 funds tracked by Wall St. Rank held CTS Corp as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.